Enodia Therapeutics agreed to acquire Kezar Life Sciences’ Sec61‑based discovery and development assets, obtaining extensive preclinical datasets and chemical space for Sec61 modulation. Kezar will receive $1 million upfront and is eligible for up to $127 million in milestone payments plus tiered royalties, enabling Enodia to deepen its targeted protein degradation efforts centered on co‑translational control. Enodia framed the transaction as a strategic fit to accelerate selective Sec61 modulation and strengthen rational small‑molecule design with integrated proteomics and Cryo‑EM datasets. The deal underscores continued M&A activity around novel modalities—targeted degradation and translocon biology—that investors view as high‑value discovery engines.